Cargando…

Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy

BACKGROUND: Patients with psoriasis are often concerned about the risk of serious infection associated with systemic psoriasis treatments. OBJECTIVES: To develop and externally validate a prediction model for serious infection in patients with psoriasis within 1 year of starting systemic therapies....

Descripción completa

Detalles Bibliográficos
Autores principales:	Yiu, Z.Z.N., Sorbe, C., Lunt, M., Rustenbach, S.J., Kühl, L., Augustin, M., Mason, K.J., Ashcroft, D.M., Griffiths, C.E.M., Warren, R.B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850093/ https://www.ncbi.nlm.nih.gov/pubmed/30430546 http://dx.doi.org/10.1111/bjd.17421

Ejemplares similares

Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta‐analysis of randomized controlled trials
por: Rungapiromnan, W., et al.
Publicado: (2017)

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
por: Yiu, Z.Z.N., et al.
Publicado: (2018)

Persistence and effectiveness of nonbiologic systemic therapies for moderate‐to‐severe psoriasis in adults: a systematic review
por: Mason, K.J., et al.
Publicado: (2019)

A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real‐world populations in psoriasis
por: Yiu, Z.Z.N., et al.
Publicado: (2019)

Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study
por: Rungapiromnan, W., et al.
Publicado: (2019)

Risk of COVID‐19 infection in adult patients with atopic eczema and psoriasis: a single‐centre cross‐sectional study
por: Yiu, Z.Z.N., et al.
Publicado: (2021)

Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis
por: Iskandar, I.Y.K., et al.
Publicado: (2017)

Antibody responses to single‐dose SARS‐CoV‐2 vaccination in patients receiving immunomodulators for immune‐mediated inflammatory disease
por: Al‐Janabi, A., et al.
Publicado: (2021)

Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
por: Yiu, Zenas Z.N., et al.
Publicado: (2018)

The global state of psoriasis disease epidemiology: a workshop report
por: Griffiths, C.E.M., et al.
Publicado: (2017)

Nonadherence to psoriasis medication as an outcome of limited coping resources and conflicting goals: findings from a qualitative interview study with people with psoriasis
por: Thorneloe, R.J., et al.
Publicado: (2016)

Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis
por: Yiu, Zenas Z.N., et al.
Publicado: (2016)

Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest
por: Reich, K., et al.
Publicado: (2015)

Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study
por: Warren, R.B., et al.
Publicado: (2018)

Incidence, prevalence and mortality of patients with psoriasis: a U.K. population‐based cohort study
por: Springate, D.A., et al.
Publicado: (2016)

Incidence of serious gastrointestinal events among tildrakizumab‐treated patients with psoriasis: Letter to the Editor
por: Gooderham, M., et al.
Publicado: (2019)

Which PASI Outcome Is Most Relevant to the Patients in Real-World Care?
por: Kirsten, Natalia, et al.
Publicado: (2021)

Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register
por: Yiu, Zenas Z. N., et al.
Publicado: (2020)

Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms
por: Warren, RB, et al.
Publicado: (2009)

Giant condylomata acuminata of Buschke and Lowenstein: A peristomal variant
por: Yiu, Z.Z.N., et al.
Publicado: (2014)

Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
por: Iskandar, Ireny Y.K., et al.
Publicado: (2018)

National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study
por: Parisi, Rosa, et al.
Publicado: (2020)

Primary care‐based screening for cardiovascular risk factors in patients with psoriasis
por: Rutter, M.K., et al.
Publicado: (2016)

Polymorphisms in the PTPN22 region are associated with psoriasis of early onset
por: Smith, RhLl, et al.
Publicado: (2008)

Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)
por: Mahil, S.K., et al.
Publicado: (2019)

Editorial: fixed‐dose combination calcipotriol/betamethasone dipropionate foam in the treatment of patients with psoriasis
por: Lebwohl, M., et al.
Publicado: (2021)

The top 10 research priorities for psoriasis in the U.K.: results of a James Lind Alliance psoriasis Priority Setting Partnership
por: Majeed‐Ariss, R., et al.
Publicado: (2019)

Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management
por: Al-Janabi, A, et al.
Publicado: (2022)

Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial
por: Warren, R.B., et al.
Publicado: (2020)

The incidence of psoriasis in Chile: an analysis of the National Waiting List Repository
por: Lecaros, C., et al.
Publicado: (2021)

What are the barriers to physical activity in patients with chronic plaque psoriasis?
por: Auker, L., et al.
Publicado: (2020)

Addressing challenges associated with long‐term topical treatment and benefits of proactive management in patients with psoriasis
por: Lebwohl, M., et al.
Publicado: (2021)

Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort study
por: Phan, Duc Binh, et al.
Publicado: (2023)

‘Mind the gap’: what patients and clinicians believe is ‘unknown’ about psoriasis
por: Majeed‐Ariss, R., et al.
Publicado: (2020)

Safety of selective IL‐23p19 inhibitors for the treatment of psoriasis
por: Crowley, J.J., et al.
Publicado: (2019)

Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients’ Medication Beliefs and Habit Strength
por: Thorneloe, Rachael J., et al.
Publicado: (2018)

Fertility Trends and Adverse Pregnancy Outcomes in Female Patients With Psoriasis in the UK
por: Chen, Teng-Chou, et al.
Publicado: (2023)

A novel mutation in IL36RN underpins childhood pustular dermatosis
por: Ellingford, J.M., et al.
Publicado: (2015)

The role of the interleukin‐23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis
por: Egeberg, A., et al.
Publicado: (2020)

Network meta‐analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method
por: Mrowietz, U., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_27b2f8rs2qm3dpgtts6f5t02fj